Dialog Box

Rare cancers occur in fewer than 6 per 100,000 people per year

In 2015, around 1 in 3 Australians diagnosed with cancer had a rare or less common cancer.

That same year, rare and less common cancers accounted for a disproportionately high 1 in 2 cancer-related deaths.

Find out more

Latest News View all news


ESMO attendees were treated to the results from 2 fantastic studies from Spain investigating genomic signatures in sinonasal cancers (SNCs), neuroendocrine tumours (NETs) and neuroendocrine carcinomas (NECs).


The responses to the Senate Inquiry into equitable access to diagnosis and treatment for individuals with rare and less common cancers are now available to read on the Parliament of Australia website.


Rare Cancers Australia and Canteen have launched their follow up report on rare cancers, Counting the cost: How we can assess the true value of investing in cancer treatment.


Australians with leiomyosarcoma or liposarcoma will now be able to access the novel anti-tumour agent Yondelis (trabectedin) at a cost of approximately $30 per script following its PBS listing in August 2023.

Supported by Rare Cancers Australia

Rare Cancers Australia (RCA) is determined to increase awareness, highlight the need for further research and initiate policy discussion and action to improve the lives and outcomes of all Australians living with rare or less common cancer. RCA is currently working with government, clinicians and industry for change